H.R. 9699

H.R. 9699: To require the Department of Health and Human Services to release documents, communications, and other information relating to most favored nation pricing agreements and other private or confidential drug pricing deals struck with manufacturer

Introduced Judy Chu (D) HOUSE_BILL — 119th Congress
Plain English Summary

H.R. 9699 requires the Department of Health and Human Services (HHS) to publicly release documents and communications related to most favored nation pricing agreements and other private or confidential drug pricing deals made with pharmaceutical manufacturers. The goal of the bill is to increase transparency in drug pricing and ensure that the public has access to information about how drug prices are negotiated.

Positive Media Summary

Supporters of H.R. 9699 have praised the bill for promoting transparency in the pharmaceutical industry, arguing that it could lead to lower drug prices and greater accountability among drug manufacturers. Advocates believe that making these documents public will empower consumers and healthcare providers to make informed decisions about medication costs.

Negative Media Summary

Critics of H.R. 9699 have raised concerns that the bill could undermine the confidentiality of negotiations between the government and drug manufacturers, potentially leading to higher prices in the long run. Some argue that releasing sensitive pricing information may discourage manufacturers from participating in negotiations, ultimately harming access to affordable medications.

Conflict of Interest Analysis Deep Analysis
3/10
Risk Level
Low
Total Donations
$0
PAC Percentage
0%
Policy Area
Health

The analysis of H.R. 9699 reveals no direct industry overlaps between the sponsor Judy Chu's top donor industries and the subject matter of the bill, which focuses on drug pricing agreements. While there is significant lobbying activity in the healthcare sector, particularly from the American Dental Association with a substantial contribution of $1,100,000, this does not directly correlate with conflicts regarding the bill's intent to increase transparency in drug pricing. The absence of direct financial ties between the bill's objectives and the sponsor's donor industries suggests a low risk of conflict of interest. Voters should be aware that while lobbying exists, it does not imply a direct influence on the legislation at hand.

Lobbying Activity — Who's Pushing?

Organizations that lobbied on issues related to this bill's policy area.

Client Lobbying Firm Amount
AMERICAN DENTAL ASSOCIATION AMERICAN DENTAL ASSOCIATION $1,100,000
CELLEBRITE INC. CELLEBRITE INC. $70,000
ANIMAL HEALTH INSTITUTE ANIMAL HEALTH INSTITUTE $55,000
SAFE KIDS WORLDWIDE SAFE KIDS WORLDWIDE $25,000
AMERICAN CONCRETE PIPE ASSOCIATION EDMUND GRABER $20,000
MATERIALS RESEARCH SOCIETY HILLSTAFFER, LLC $15,000
NAFA FLEET MANAGEMENT ASSOCIATION HILLSTAFFER, LLC $15,000
BETTENDORF IA EDMUND GRABER $10,000
NATIONAL UTILITY CONTRACTORS ASSN EDMUND GRABER $10,000
ILLINOIS PUBLIC TRANSIT ASSN EDMUND GRABER $10,000
NATIONAL COOPERATIVE BUSINESS ASSOCIATION NATIONAL COOPERATIVE BUSINESS ASSOCIATION undisclosed
FMC CORPORATION RED FLAG CONSULTING USA(FORMALLY KNOWN AS INTERNATIONAL BUSINESS-GOVERNMENT COUNSELLORS, INC) undisclosed
ASSOCIATION FOR DIPLOMATIC STUDIES AND TRAINING HILLSTAFFER, LLC undisclosed
NATIONAL ACADEMY OF NEUROPSYCHOLOGY HILLSTAFFER, LLC undisclosed
THE ETHYLENE OXIDE STERILIZATION ASSOCIATION, INC HILLSTAFFER, LLC undisclosed

Source: Senate Lobbying Disclosure Act (LDA) filings, 2026

Sponsor's Top Donor Industries

Top industries funding Judy Chu, ranked by total contributions.

Health Professionals $120,000,000
Individuals: $120,000,000 PACs: $0
Retired $37,500,000
Individuals: $37,500,000 PACs: $0

Source: OpenSecrets.org (Center for Responsive Politics)

TheBillRoom is free and independent. No ads, no subscriptions, no political funding. If this analysis was useful, reader support keeps it running.
Support Us